Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cardiosafety

Nonclinical Cardiosafety Assays in Early Drug Development... [Pg.396]

Nondinical assessment of cardiac safety must be performed for a compound to qualify to be submitted to the health authorities to begin studies in man. For this purpose the regulatory bodies require that the cardiosafety assays should follow the principles of GLP wherever possible. The following assays/technologies are frequently used to predict potential clinical QT liability. [Pg.396]

Cardiosafety risk assessment in early drug discovery projects focuses on hERG as the most frequently hit and well validated target linked to TdP. In pharmaceutical settings, it is common to use a combination of in silico and high-throughput experimental assays to assess LQT risk for larger numbers of compounds [8, 14[. [Pg.401]

PREDICTIVITY OF AVAILABLE CARDIOSAFETY ASSAYS 3.5.1 In silico predictions... [Pg.38]

See other pages where Cardiosafety is mentioned: [Pg.284]    [Pg.387]    [Pg.388]    [Pg.388]    [Pg.389]    [Pg.390]    [Pg.392]    [Pg.394]    [Pg.396]    [Pg.400]    [Pg.401]    [Pg.403]    [Pg.403]    [Pg.403]    [Pg.406]    [Pg.406]    [Pg.410]    [Pg.412]    [Pg.46]   
See also in sourсe #XX -- [ Pg.387 ]



SEARCH



Nonclinical Cardiosafety Assays in Early Drug Development

© 2024 chempedia.info